Cargando…

P1004: EFFECT AND MOLECULAR MECHANISM OF TQ05105, A NOVEL SMALL MOLECULE INHIBITOR OF JAK2 IN MYELOPROLIFERATIVE NEOPLASM

Detalles Bibliográficos
Autores principales:	Zhang, W., Liu, J., Shi, Z., Yang, L., Li, B., Xiao, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429026/ http://dx.doi.org/10.1097/01.HS9.0000846884.97738.71

Ejemplares similares

S246: JAK/ROCK INHIBITOR TQ05105 FOR GLUCOCORTICOID-REFRACTORY OR -DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE: UPDATED RESULTS OF A PHASE 1B/2 STUDY
por: Zhao, Yanmin, et al.
Publicado: (2023)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
por: Zhao, Ailin, et al.
Publicado: (2023)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
por: Bhuria, Vikas, et al.
Publicado: (2023)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
por: Zaroogian, Zachary, et al.
Publicado: (2023)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS
por: Petiti, J., et al.
Publicado: (2022)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
por: Holl, Kristin, et al.
Publicado: (2023)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
por: Choong, Meng Ling, et al.
Publicado: (2013)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

P1071: IMPACT OF ACETYLSALICYLIC ACID DOSAGE ON INCIDENCE OF THROMBOSIS AND MORTALITY IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.
por: Wild, A., et al.
Publicado: (2022)

P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS
por: Garrote, M., et al.
Publicado: (2022)

P1705: PATIENT-REPORTED OUTCOMES IN MYELOPROLIFERATIVE NEOPLASMS IN CLINICAL TRIALS: A SYSTEMATIC REVIEW
por: Oliva, E. N., et al.
Publicado: (2022)

P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
por: Shivarov, Velizar, et al.
Publicado: (2023)

P994: GERMLINE SINGLE-NUCLEOTIDE VARIANTS (SNV) IN THE JAK-STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)
por: Diepers, Alice, et al.
Publicado: (2023)

Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil
por: Torres, Dania G., et al.
Publicado: (2023)

P1050: NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE
por: Leone, Aldo, et al.
Publicado: (2023)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
por: Bellido, Mar, et al.
Publicado: (2012)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
por: Anelli, Luisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0f382okslmosn5dcj5nvcosqho